Bafna Pharmaceuticals (NSE:BAFNAPH) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
58 GF Score
Price ₹323.50
GF Value ₹86.06
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NSE:BAFNAPH
58GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹323.50 is trading 275.9% above its estimated GF Value™ of ₹86.06. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Short Ratio:
  • GF Value™: ₹86.06 vs. price of ₹323.50 (275.9% above fair value)
  • GF Score™: 58/100 with 9 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the manufacturing and trading of finished pharmaceutical formulations. It produces a range of generic and branded formulations across therapeutic segments including cardiology, diabetology, and lifestyle or potent drugs, with capabilities in tablets, capsules, and other oral solid dosage forms. The company operates manufacturing facilities in India and supplies its products to domestic and international markets, including regulated and emerging markets. Its revenue comes primarily from the sale of pharmaceutical formulations, supplemented by contract manufacturing and trading activities. The company operates as a single business segment, pharmaceuticals manufacturing and trading, and serves hospitals, distributors, and healthcare institutions through its product portfolio.
58GF Score

Get the complete analysis for NSE:BAFNAPH

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹323.50
Price
₹86.06
GF Value